FI961494L - Farmaseuttisia koostumuksia ja niiden käyttö, etenkin hermoston rappeutumissairauksien hoitamiseksi - Google Patents
Farmaseuttisia koostumuksia ja niiden käyttö, etenkin hermoston rappeutumissairauksien hoitamiseksi Download PDFInfo
- Publication number
- FI961494L FI961494L FI961494A FI961494A FI961494L FI 961494 L FI961494 L FI 961494L FI 961494 A FI961494 A FI 961494A FI 961494 A FI961494 A FI 961494A FI 961494 L FI961494 L FI 961494L
- Authority
- FI
- Finland
- Prior art keywords
- treatment
- pharmaceutical compositions
- neurodegenerative diseases
- neurodegenerative
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
- A01N43/04—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Environmental Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Dentistry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9311774A FR2710846B1 (fr) | 1993-10-04 | 1993-10-04 | Compositions pharmaceutiques et leur utilisation, notamment dans le traitement des maladies neurogénératives. |
| FR9311774 | 1993-10-04 | ||
| FR9401142 | 1994-09-29 | ||
| PCT/FR1994/001142 WO1995009916A1 (fr) | 1993-10-04 | 1994-09-29 | Compositions pharmaceutiques et leur utilisation, notamment pour le traitement des maladies neurodegeneratives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI961494A0 FI961494A0 (fi) | 1996-04-03 |
| FI961494L true FI961494L (fi) | 1996-04-03 |
| FI117707B FI117707B (fi) | 2007-01-31 |
Family
ID=9451499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI961494A FI117707B (fi) | 1993-10-04 | 1996-04-03 | Menetelmiä terapeuttisesti käyttökelpoisen yhdistelmä-DNA-vektorin valmistamiseksi |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7273854B1 (fi) |
| EP (2) | EP1598420A3 (fi) |
| JP (2) | JP3937446B2 (fi) |
| AT (1) | ATE311446T1 (fi) |
| AU (1) | AU698242B2 (fi) |
| CA (1) | CA2173338C (fi) |
| DE (1) | DE69434564T2 (fi) |
| DK (1) | DK0722496T3 (fi) |
| ES (1) | ES2253739T3 (fi) |
| FI (1) | FI117707B (fi) |
| FR (1) | FR2710846B1 (fi) |
| NO (1) | NO322063B1 (fi) |
| WO (1) | WO1995009916A1 (fi) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2736915B1 (fr) | 1995-07-19 | 1997-08-22 | Rhone Poulenc Rorer Sa | Variants de la proteine p53 et utilisations therapeutiques |
| FR2746815A1 (fr) * | 1996-03-26 | 1997-10-03 | Pasteur Institut | Sequences en amont du gene sm 22, vecteurs les contenant et leurs utilisations therapeutiques, notamment dans le traitement des maladies vasculaires |
| AU4394697A (en) * | 1996-08-13 | 1998-03-06 | Trustees Of Princeton University, The | P53 mutant |
| US5876972A (en) * | 1996-09-23 | 1999-03-02 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Nucleic acid molecules coding for tumor suppressor proteins and methods for their isolation |
| FR2781979B1 (fr) | 1998-08-05 | 2001-06-08 | Fond Jean Dausset Ceph | Modele animal presentant une deficience de la memoire et/ou des troubles comportementaux |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5532220A (en) | 1987-08-31 | 1996-07-02 | The Regents Of The University Of California | Genetic mechanisms of tumor suppression |
| US5672344A (en) | 1987-12-30 | 1997-09-30 | The Regents Of The University Of Michigan | Viral-mediated gene transfer system |
| US5716826A (en) | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
| US5087617A (en) | 1989-02-15 | 1992-02-11 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
| WO1991018088A1 (en) * | 1990-05-23 | 1991-11-28 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Adeno-associated virus (aav)-based eucaryotic vectors |
| JPH06501160A (ja) * | 1990-09-17 | 1994-02-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 細胞の増殖をコントロールするための方法及び組成物 |
| WO1992015680A1 (en) * | 1991-03-06 | 1992-09-17 | Board Of Regents, The University Of Texas System | Methods and compositions for the selective inhibition of gene expression |
| FR2675803B1 (fr) * | 1991-04-25 | 1996-09-06 | Genset Sa | Oligonucleotides fermes, antisens et sens et leurs applications. |
| US6261834B1 (en) * | 1991-11-08 | 2001-07-17 | Research Corporation Technologies, Inc. | Vector for gene therapy |
| EP0677099B1 (en) * | 1992-12-31 | 2005-11-30 | Dana-Farber Cancer Institute, Inc. | Enhancer sequence for modulating expression in epithelial cells |
| US5624803A (en) * | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
| US5700657A (en) | 1993-12-13 | 1997-12-23 | Genzyme Corporation | Vectors and vector systems including genes encoding tumor suppressor proteins and producer cells transformed thereby |
| US5731172A (en) | 1994-03-09 | 1998-03-24 | Sumitomo Pharmaceuticals Company, Ltd. | Recombinant adenovirus and process for producing the same |
| US5641750A (en) | 1995-11-29 | 1997-06-24 | Amgen Inc. | Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product |
| US5641749A (en) | 1995-11-29 | 1997-06-24 | Amgen Inc. | Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product |
-
1993
- 1993-10-04 FR FR9311774A patent/FR2710846B1/fr not_active Expired - Lifetime
-
1994
- 1994-09-29 EP EP05016159A patent/EP1598420A3/fr not_active Withdrawn
- 1994-09-29 CA CA002173338A patent/CA2173338C/fr not_active Expired - Lifetime
- 1994-09-29 DE DE69434564T patent/DE69434564T2/de not_active Expired - Lifetime
- 1994-09-29 ES ES94928933T patent/ES2253739T3/es not_active Expired - Lifetime
- 1994-09-29 AU AU78162/94A patent/AU698242B2/en not_active Expired
- 1994-09-29 EP EP94928933A patent/EP0722496B1/fr not_active Expired - Lifetime
- 1994-09-29 DK DK94928933T patent/DK0722496T3/da active
- 1994-09-29 AT AT94928933T patent/ATE311446T1/de active
- 1994-09-29 WO PCT/FR1994/001142 patent/WO1995009916A1/fr not_active Ceased
- 1994-09-29 JP JP51063995A patent/JP3937446B2/ja not_active Expired - Fee Related
-
1996
- 1996-03-26 NO NO19961220A patent/NO322063B1/no not_active IP Right Cessation
- 1996-04-03 FI FI961494A patent/FI117707B/fi not_active IP Right Cessation
-
2000
- 2000-05-26 US US09/578,453 patent/US7273854B1/en not_active Expired - Fee Related
-
2007
- 2007-01-19 JP JP2007010778A patent/JP2007190020A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP3937446B2 (ja) | 2007-06-27 |
| FI961494A0 (fi) | 1996-04-03 |
| EP0722496B1 (fr) | 2005-11-30 |
| JP2007190020A (ja) | 2007-08-02 |
| CA2173338C (fr) | 2009-05-05 |
| AU7816294A (en) | 1995-05-01 |
| FI117707B (fi) | 2007-01-31 |
| ATE311446T1 (de) | 2005-12-15 |
| FR2710846A1 (fr) | 1995-04-14 |
| NO322063B1 (no) | 2006-08-07 |
| CA2173338A1 (fr) | 1995-04-13 |
| EP1598420A3 (fr) | 2007-12-12 |
| DK0722496T3 (da) | 2006-04-03 |
| EP1598420A2 (fr) | 2005-11-23 |
| US7273854B1 (en) | 2007-09-25 |
| JPH09503915A (ja) | 1997-04-22 |
| NO961220L (no) | 1996-03-26 |
| DE69434564D1 (de) | 2006-01-05 |
| WO1995009916A1 (fr) | 1995-04-13 |
| AU698242B2 (en) | 1998-10-29 |
| EP0722496A1 (fr) | 1996-07-24 |
| ES2253739T3 (es) | 2006-06-01 |
| FR2710846B1 (fr) | 1995-12-22 |
| NO961220D0 (no) | 1996-03-26 |
| DE69434564T2 (de) | 2006-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI933770A7 (fi) | Farmaseuttisia koostumuksia ihotautien hoitamiseen | |
| FI20115742L (fi) | Mometasonifuroaatin käyttö lääkkeen valmistuksessa | |
| FI962249A7 (fi) | Substituoituja pyratsolyylibentseenisulfonamideja tulehduksen hoitoa varten | |
| MX9202839A (es) | 4-aminoquinolinas y composiciones farmaceuticas de las mismas. | |
| FI972308A0 (fi) | 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi | |
| FI963883A7 (fi) | Farmaseuttisia valmisteita ja lääkeaineita endoteelin toimintahäiriön ehkäisemiseksi ja hoitamiseksi | |
| FI933902A7 (fi) | Substituoidut sykloheksaanijohdannaiset sairauksien hoitamiseksi | |
| FI941836A7 (fi) | 3-deoksioligosakkaridit, menetelmiä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset | |
| FI930860A7 (fi) | Tropolonijohdoksia ja niiden farmaseuttisia koostumuksia iskeemisten s airauksien ehkäisemiseen ja hoitamiseen | |
| DE69420229D1 (de) | Pharmazeutische Zusammensetzung zur Behandlung von AIDS | |
| FI955786A7 (fi) | Luonnontuotteiden ja vastaavien yhdisteiden käyttö sydän- ja verisuonisairauksien hoitoon | |
| BR9806083A (pt) | Composi-Æo farmac-utica para o tratamento da hapattite c | |
| FI956353L (fi) | Farmaseuttiset valmisteet ja niiden käyttö etenkin neurodegeneratiivisten sairauksien hoidossa | |
| FI961494L (fi) | Farmaseuttisia koostumuksia ja niiden käyttö, etenkin hermoston rappeutumissairauksien hoitamiseksi | |
| NO934832D0 (no) | Farmasoeytisk sammensetning for forhindring eller behandling av ar terioscherose | |
| EE03437B1 (et) | Benseenamiidid neurodegeneratiivsete haiguste ravimiseks | |
| IL105061A (en) | Pharmaceutical compositions for the treatment of neurodegenerative diseases comprising VIP analogues and fragments thereof | |
| FI963264A7 (fi) | Tromboksaani A2-välitteisten sairauksien ennaltaestoon ja hoitoon tarkoitettu aine | |
| FI944687L (fi) | Koostumus likinäköisyyden ennaltaehkäisemiseksi ja hoitamiseksi | |
| FI911533A7 (fi) | Bentsoksatsiini-johdannaisia, menetelmä niiden valmistamiseksi ja niiden käyttö sairauksien hoitamiseen tai ennalta ehkäisemiseksi | |
| BR9610851A (pt) | Composto processo de preparação de composto medicamento composição farmacêuticas e utilização do composto | |
| FI950649L (fi) | Substituoidut sykloheksanoliesterit, niiden käyttö sairauksien hoitamiseksi ja farmaseuttiset valmisteet | |
| ITRM920305A1 (it) | Composizione farmaceutica per il trattamento dello shock, particolarmente dello shock cardiogeno e dello shock settico. | |
| BR9507732A (pt) | Composição farmacêutica para o tratamento de glaucoma | |
| EE200200698A (et) | Ravimid neurodegeneratiivsete haiguste ennetamiseks ja raviks |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Transfer of assignment of patent |
Owner name: AVENTIS PHARMA S.A. |
|
| FG | Patent granted |
Ref document number: 117707 Country of ref document: FI |
|
| MA | Patent expired |